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Abstract
Clear cell ovarian cancer is an epithelial ovarian cancer histotype that is less responsive to chemotherapy and carries poorer
prognosis than serous and endometrioid histotypes. Despite this, patients with these tumors are treated in a similar fashion
as all other ovarian cancers. Previous genomic analysis has suggested that clear cell cancers represent a unique tumor
subtype. Here we generated the first whole genomic expression profiling using epithelial component of clear cell ovarian
cancers and normal ovarian surface specimens isolated by laser capture microdissection. All the arrays were analyzed using
BRB ArrayTools and PathwayStudio software to identify the signaling pathways. Identified pathways validated using serous,
clear cell cancer cell lines and RNAi technology. In vivo validations carried out using an orthotopic mouse model and
liposomal encapsulated siRNA. Patient-derived clear cell and serous ovarian tumors were grafted under the renal capsule of
NOD-SCID mice to evaluate the therapeutic potential of the identified pathway. We identified major activated pathways in
clear cells involving in hypoxic cell growth, angiogenesis, and glucose metabolism not seen in other histotypes. Knockdown
of key genes in these pathways sensitized clear cell ovarian cancer cell lines to hypoxia/glucose deprivation. In vivo
experiments using patient derived tumors demonstrate that clear cell tumors are exquisitely sensitive to antiangiogenesis
therapy (i.e. sunitinib) compared with serous tumors. We generated a histotype specific, gene signature associated with
clear cell ovarian cancer which identifies important activated pathways critical for their clinicopathologic characteristics.
These results provide a rational basis for a radically different treatment for ovarian clear cell patients.
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Introduction
Clear cell ovarian cancer (CCOC) was originally described as a
mesonephroma ovarii in 1939 by Schiller due to its similar
appearance to renal cell carcinoma [1]. Further studies since that
time, has provided evidence that these tumors are of ovarian origin
[2,3,4,5,6] CCOC represents 4–14% of all epithelial ovarian
cancers and its clinical behavior differs from that of the other
epithelial histotypes [4,6,7]. Patients with stage I CCOC have a
27% risk of recurrence [8] with a five year survival rates for of
60% compared with 80%, for serous tumors [8]. Patients with late
stage disease also have a poorer prognosis when compared to
patients with advanced stage serous ovarian cancer [8]. This likely
reflects CCOC’s lower rate of response to the traditional
platinum/taxane-based chemotherapy, reported to be between
11–45% during first-line treatment [8,9]. CCOC patients also
have higher rates of thromboembolic events when compared to
patients with other epithelial ovarian cancer histotypes [10].
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e21121Histologically, CCOC cells are ‘‘clear’’ due to the high
cytoplasmic glycogen content that is an artifact of H & E staining
[11,12]. CCOC has been found to have ultrastructural similarity
to clear cell carcinoma of the vagina and endometrium. This
ultrastructural similarity carries over to genetic similarity as well.
Zorn et al. found similar gene expression profiles of clear cell
tumors of the ovary, endometrium, and kidney with use of an
11,000 probeset array [13]. This genetic overlap, however, did not
extend to the comparison of serous and endometrioid histotypes of
ovarian and endometrial origin. Another gene expression profile of
CCOC using a 7,129 probe set array demonstrated it to be very
distinct from the other histotypes [14]. These studies suggest that
there are similar pathways that lead to the clear cell histotype
regardless of the organ of origin.
In this study, we present the results of the first whole genome
expression profiling of microdissected CCOC samples. Gene
ontology and pathway analysis identified major activated pathways
involved in hypoxic cell growth, angiogenesis, and glucose
metabolism. We hypothesized that these pathways might provide
a mechanism for the aggressive clinical nature of CCOC. We
demonstrate that clear cell cancer cell lines survive better than
serous cell lines under hypoxia and glucose deprived conditions
and this is in part due to these activated pathways involving HIF1
a and enolase. In vivo experiments using patient derived tissues
demonstrate that clear cell tumor xenografts are exquisitely
sensitive to antiangiogenesis therapy (sunitinib) compared with
serous tumors. Combination therapy of sunitinib and RNAi to
HIF1a and enolase demonstrates synergistic anti tumor activity.
These results provide a rational basis for specific therapy in these
patients.
Materials and Methods
Ethics Statement
Ovarian cancer tissue specimens were obtained with informed
written consent from patients undergoing bilateral salpingoophor-
ectomy at Vancouver General Hospital following a protocol
approved by the University of British Columbia Clinical Research
Ethics Board, Canada. Specimens used for profiling were collected
under the protocols approved by the institutional review boards of
the Brigham and Women’s Hospital (Boston, MA, USA) and were
obtained with informed written consent from the patients. Animal
care and experiments were carried out in accordance with the
guidelines and approval by the University of British Columbia -
British Columbia Cancer Agency Research Ethics Board (UBC
BCCA REB) (Number: H04-60131) and M.D. Anderson Cancer
Center Institutional Animal Care and Use Committee, USA
(IACUC Number: 12-02-18233).
Tissue specimens, microdissection, RNA isolation and
amplification
Ten clear cell ovarian cancer specimens were obtained from the
primary tumors of previously untreated ovarian cancer patients at
the Brigham and Women’s Hospital (Boston, MA). A set of 10
normal ovarian surface epithelium (OSE) cytobrushing specimens
was also obtained from the normal ovaries of patients at the time
of surgery for benign indications. Frozen sections (7 mm) were
affixed onto FRAME slides (Leica, Wetzlar, Germany), fixed in
70% alcohol for 30 seconds, stained by 1% methyl green, rinsed in
deionized water, and air-dried. Microdissection was performed
using a MD LMD laser microdissecting microscope (Leica).
Tumor cells (,5,000) were dissected for each case. RNA was
isolated, extracted, and purified as previously described [15]. In
order to generate sufficient cRNA for microarray analysis, a two-
cycle amplification protocol (Affymetrix) was utilized that has been
previously described [16].
Microarray analysis
All array data is Minimum Information About a Microarray
Experiment (MIAME) compliant and the raw data has been
deposited in a MIAME compliant database (GEO, Accession
Number: GSE29450)
Data Normalization. Global normalization at a target value
of 500 was applied to all 20 of the arrays under consideration using
Gene Chip Operating Software (Affymetrix). Normalized data
were uploaded into the National Cancer Institute’s Microarray
Analysis Database (mAdb) for quality control screening and
collation prior to downstream analyses (http://nciarray.nci.nih.
gov/index.shtml). Biometric Research Branch (BRB) ArrayTools
version 3.2.2 software developed by Drs. Richard Simon and Amy
Peng Lam of the Biometrics Research Branch of the National
Cancer Institute was used to filter and complete the statistical
analysis of the array data. BRB-ArrayTools is a multifunctional
Excel add-in that contains utilities for processing and analyzing
microarray data using the R version 2.0.1 environment (R
Development Core Team, 2004). Hybridization control probe
sets and probe sets scored as absent at a1=0.05 or marginal (M) at
a2=0.065 were excluded. In addition, only those transcripts
present in greater than 50% of the arrays and displaying a
variance in the top 50th percentile were evaluated.
Class comparison, gene ontology, and pathway
analysis. A multivariate permutation test in BRB ArrayTools
was utilized to identify differentially expressed genes. A list of
probesets containing ,10% false positives at a confidence of 95%
was obtained after a total of 2,000 permutations. Differential
expression was considered significant at a p-value of ,0.001. A
random variance t test and global assessment was performed as
previously described [16].
In order to identify particular functional categories of genes that
were highly enriched in CCOC, we identified gene ontology (GO)
categories that were statistically significant among the list of
differentially regulated genes. A Hotelling T-square test was
performed to identify significant GO categories. In order to
identify signaling pathways involved in CCOC, the gene list that
was generated from the microarray analysis was imported into
PathwayStudio software (Ariadne Inc, Rockville, MD).
Quantitative RT-PCR
Quantitative real-time PCR was performed for the 10 clear cell
ovarian cancer samples and the 10 OSE samples. 50 ng of the
double-amplified product was used from all 20 samples using
primer sets specific for 12 selected genes and the housekeeping
genes GAPDH, GUSB, and cyclophillin. An iCycler iQ Real-
Time PCR Detection System (Bio-Rad , Hercules, CA) was used
in conjunction with the One-Step qRT-PCR with SYBR Green
kit (Invitrogen Life Technologies, Inc., Carlsbad, CA) according to
previously described cycling conditions [17]. To calculate the
relative expression for each gene, the 2
2DDCT method was used
averaging the CT values for the three housekeeping genes.
Cell lines and culture conditions
The human clear cell ovarian cancer cell lines ES-2, TOV21G,
and RMG1, and the serous cell lines OVCA 420 and OVCA 432
were maintained in a 1:1 mixture of medium 199 (Invitrogen Life
Technologies, Inc. Carlsbad, CA) and medium 105 (Sigma, St.
Louis, MO), supplemented with 10% fetal bovine serum (FBS) and
1% L-glutamine. The human serous ovarian cancer cell lines SK-
OV-3 and OVCAR-3 were maintained in RPMI 1640 (Invitrogen
A Genomic Approach for Personalized Medicine
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glutamine. CAOV3 and OVCA 429 cells were maintained in
DMEM (Invitrogen Life Technologies) supplemented with 10%
FBS and 1% L-glutamine. ES-2, TOV21G, SKOV3, OVCAR3
CAOV3 and RMG1 cell lines were purchased from American
Type Culture Collection and Japanese Collection of Research
Bioresources. OVCAR 420, OVCAR 432 and OVCA 429 were
obtained from the Laboratory of Gynecologic Oncology at
Brigham and Women’s Hospital [18].
Hypoxia/Glucose deprivation conditions
Cells from clear cell and serous ovarian origins were plated and
placed in the conditions of normoxia with DMEM, 10% FBS,1%
L-glutamine or hypoxia with glucose-free DMEM, 10% FBS,1%
L-glutamine (Invitrogen Life Technologies). Hypoxia was pro-
duced by flushing an incubator (Thermo Forma Series II, Thermo
Fischer Scientific, Inc., Waltham, MA) with nitrogen to achieve a
mixture of 1% O2,5 %C O 2, and 94% nitrogen. The incubator
was maintained at 37uC.
Cell proliferation assays
The cancer cell lines were seeded in 96-well plates in 8 replicates
(ES-2, TOV21G, OVCA 420, SK-OV-3, OVCAR-3, OVCA-
420, OVCA-429: 5610
2 cells per well, CAOV3, OVCA-432,
RMG1: 1610
3 cells/well) and placed in either conditions of
normoxia with media containing normal glucose (NN) or hypoxia/
glucose deprivation (HG) for 24, 48, and 72 hours. After these
periods, relative numbers of viable cells were measured using the
fluorometric, resazurin-based Cell Titer Blue assay (Promega,
Madison, WI) according to the manufacturer’s instructions at
560Ex/590Em nm in a Victor3 multi-label counter (PerkinElmer,
Germany). Doubling times for each cell line under each condition
were calculated using Prism 4.02 Software (Graph Pad, San
Diego, USA). Fold change in doubling time of hypoxia/glucose
deprivation compared to normal conditions was calculated and
averaged for each cell line over two experiments. Average fold
change was calculated for the serous cell lines and clear cell lines
and compared.
Cell cycling assay
The cell cycle status of the ES-2 and OVCA 420 cells were
compared in the conditions of normoxia and hypoxia/glucose
deprivation by flow cytometry. Briefly, 7.5610
4 ES2 cells and
2.0610
5 OVCA420 cells were seeded in 60 mm
2 plates in
triplicate and allowed to incubate overnight. The media was
changed on the next day, and the cells were placed under the
above conditions. After 48 hours of incubation (normoxia at 37uC
or hypoxia/glucose deprivation at 37uC), the media and adherent
cells were collected and centrifuged at 1500 xg for 5 minutes. The
pellet was washed in 2 mls phosphate-buffered saline (PBS) and
centrifuged at 1500 xg for 5 minutes. The cells were resuspended
in 200 ml of cold PBS. 2 mls of ice-cold 70% ethanol was added,
and the cells were incubated on ice for 30 minutes to permeabilize.
The cells were then centrifuged at 1500 xg for 10 minutes. The
supernatant was decanted and 900 ml of room temperature PBS
was used to resuspend the cells. 100 ml of RNAse A (10 mg/ml,
Worthington Biochemical Corp., Lakewood, NJ) and 10 mlo f
propidium iodide (1 mg/ml, Sigma) were added, and the tubes
were then incubated at 37uC for 30 minutes, avoiding light. DNA
contents were determined by flow cytometry (FACSCalibur,
Becton, Dickinson, and Company, Franklin Lakes, NJ) and the
histograms of DNA contents were analyzed using FlowJo 7.2 (Tree
Star, Inc., Ashland, OR) to characterize the population fractions
in each phase of the cell cycle.
Caspase-3 assay
The direct measurements of caspase 3 activity were made
using a caspase-3 fluorometric-kit (Invitrogen Life Technolo-
gies). Briefly, 2.0610
5 OVCA420 cells were seeded in 60 mm
2
plates and allowed to incubate overnight. On Day 0, the media
was replaced and the plates were then placed in the conditions
of normoxia/normal glucose or hypoxia/glucose deprivation.
Cells were collected at 24, 48, and 72 hours. The cells were
collected, pelleted, resuspended in 50 ml of chilled Cell Lysis
Buffer, and incubated on ice for 10 minutes. Protein concen-
tration was determined by BCA protein assay (Pierce, Rockford,
IL). 50 mlo f2 6Reaction Buffer and 10 mM DTT were added
to each 50 ml aliquot of cell lysate. 5 mlo f1m MD E V D - A F C
substrate was then added to each sample while avoiding the
light. The samples were then incubated at 37uC for 1 hour in
the dark. MEF cells (60 mm plate, 80% confluent) treated with
10 mlc y c l o h e x i m i d ea n d3 0n gT N F a were used as a positive
control. Fluorescence was then assessed in a Victor3 multi-label
counter (PerkinElmer, Germany) with 405Ex/535Em nm filters.
T h ef o l di n c r e a s ei nC a s a s e - 3 activity was determined by
relative fluorescence per mgp r o t e i n .
Necrosis assay
In order to assay for the presence of necrosis, the CytoTox-
ONE
TM homogeneous membrane integrity assay was used as
recommended by the manufacturer (Promega). This assay
measures the release of LDH from cells with damaged
membranes. Briefly, 5610
3 OVCA-420 cells were plated in a
96 well plate in triplicate. The media was changed the next day,
and the cells were placed in the conditions of either normal
oxygen/normal glucose or hypoxia/glucose deprivation.
48 hours later, the plates were removed from the incubator and
equilibrated to 22uC. In order to generate a Maximum LDH
Release Control, 2 ml of lysis solution was added to the control
wells placed in normal oxygen/normal glucose. 100 mlo f
CytoTox-ONE
TM Reagent was added to each well. After
10 minutes of incubation at 22uC, 50 ml of Stop Solution was
added to each well. The plates were shaken for 10 seconds. From
each well, 100 ml was transferred to an opaque plate and
fluorescence was recorded at 560Ex/590Em nm in a Victor3
multi-label counter (PerkinElmer, Germany). After subtracting
the culture medium background, the percent cytotoxicity was
calculated by the dividing the experimental fluorescence by the
Maximum LDH Release fluorescence.
Treatment of cell lines with siRNA oligonucleotides
Knockdown of HIF1 a a n dE n o l a s e1w a sp e r f o r m e du s i n g
siRNA oligonucleotides (Qiagen, Inc). A reverse transfection
protocol was performed using Oligofectamine (Invitrogen Life
Technologies, Inc) as recommended by the manufacturer in a
96-well plate format. For each well, 50 nM of siRNA and 0.5 ml
Oligofectamine transfection reagent was diluted in 50 mlo f
s e r u m - f r e eD M E Ma n da l l o w e dt oi n c u b a t ea tr o o mt e m p e r -
ature for 30 minutes. ES-2 cells, TOV-21G cells, and RMG-1
cells were seeded in a 96-well plate at 1.0610
4 cells, 2.0610
4
cells, and 5.0610
4 cells per well, respectively. Scrambled siRNA
was used as a negative control. 48 hours after transfection, the
media was replaced with glucose-free DMEM, and cells were
placed under the conditions of hypoxia. Growth was assessed at
0 and 24 hours by Cell Titer Blue assay (Promega). The
proliferation assays for ES2 and TOV21G cell lines were
performed using 75 nM siRNA for 24, 48 and 72 hours after
transfection.
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with or without sunitinib inhibits CCOC tumor
progression in athymic nude mice
Female athymic nude mice were purchased from the National
Cancer Institute, Frederick Cancer Research and Development
Center (Frederick, MD). ES2 cells were trypsinized, washed and
resuspended in Hanks’ balanced salt solution (Gibco, Carlsbad,
CA) and injected intraperitoneal into mice (1610
6 cells/mouse). In
order to down-regulate Enolase and HIF1 a in vivo, the respective
siRNA was employed. Non-targeting, nonspecific sequence 59-
ATT TCT CCG AAC GTG TCA CGT-39 was used as control,
while the human-specific sequences were used for Enolase (59-
GCG CAT TGG AGC AGC AGA GGT TTA39) and HIF-1 a (59
CAG TTG TCA CCA TTA GAA A-39). These target specific
siRNAs were purchased from Sigma-Aldrich and prepared as
previously described [19,20]. The lyophilized DOPC incorporated
siRNA was hydrated with PBS and injected intraperitoneal twice
weekly following our previously published protocols [21] at 5.0 mg
siRNA/200 mL suspension. The same volume of PBS injected
intraperitoneal was used as a control.
SU11248/sunitinib malate (Sutent, Pfizer) was suspended in
carboxymethylcellulose vehicle formulation, containing carboxy-
methylcellulose sodium (0.5% wt/vol), NaCl (1.8% wt/vol), Tween
80 (0.4% wt/vol), benzyl alcohol (0.9% wt/vol), and reverse osmosis
deionized water (added to final volume) and adjusted to pH 6.0 as
previously described [22]. Sunitinib structure and activity have
previously been reported [23]. Drug aliquots were prepared once
weekly and kept in the dark at 4uC. Mice were treated with 40 mg/
kg in 200 ml vehicle by gavage once daily. Daily gavage with vehicle
alonewas usedasacontrol.Sevendays afterES2cell injection,mice
were randomly divided and treated with control, Enolase or HIF1 a
siRNA-DOPC 6 sunitinib (n=10/group). Treatment was contin-
ued for 3 weeks, at which point, all mice in the experiment were
sacrificed and necropsied, and tumors were harvested. Tumor
weight and nodule count were recorded. Tumor tissue was frozen in
optimal cutting temperature (OCT) media to prepare frozen slides
for subsequent CD31 staining.
Immunohistochemical staining for CD31
Immunohistochemical staining for CD31 antigen was per-
formed on frozen slides to evaluate tumor microvessel density
(MVD). Slides were fixed in cold acetone for 10 minutes.
Endogenous peroxidase was blocked with 3% H2O2 in methanol
and nonspecific epitopes were blocked using 5% normal horse
serum and 1% normal goat serum. Slides were then incubated
with anti-mouse CD31 (1:800 dilution, PharMingen San Diego,
CA) at 4 degrees overnight. After washing with PBS, the
appropriate HRP-conjugated secondary antibody in blocking
solution was added for 1 hour at room temperature. Slides were
developed with 3, 30-diaminobenzidine (DAB) chromogen (In-
vitrogen, Carlsbad, CA) and counterstained with Gil No. 3
hematoxylin (Sigma-Aldrich, St. Louis, MO). MVD was calculat-
ed by viewing 10 representative 2006 fields per slide in each
treatment group and counting the number of microvessels per
field. A microvessel was defined as an open lumen with at least one
CD31-positive cell immediately adjacent to it.
Differential effect of sunitinib on transplantable patient-
derived ovarian cancer tumors
Six- to eight week old female NOD-SCID mice were bred by
the BC Cancer Research Centre Animal Resource Centre, BC
Cancer Agency, Vancouver, Canada. Mice were housed under
specific, pathogen-free conditions in sterile filter-top cages in high
efficiency particulate air-filtered ventilated racks, and received
sterile rodent chow and water. Ovarian cancer tissue specimens
were obtained with informed consent from patients undergoing
bilateral salpingoophorectomy at Vancouver General Hospital.
Briefly, to develop transplantable cancer tissue lines, fresh tumor
tissue was cut into small pieces and grafted into the subrenal capsule
site of female NOD-SCID mice for subsequent serial transplanta-
tionandcharacterizationaspreviouslydescribed [24,25].A panelof
ovarian cancer tissue xenograft models, i.e., three serous carcinoma
tissue lines (LTL237, 247 and 259) and one clear cell carcinoma
tissue line (LTL175) (http://livingtumorlab.com/PDC_Ovarian.
html), was used.
For Sunitinib efficacy studies, 96 pieces of tissue (46261m m
3)
from xenografts of each established tumor tissue line were grafted
under renal capsules of 24 female NOD-SCID mice, as previously
described [25]. When the implants were well-established, reaching
an average volume of about 20 to 50 mm
3 [24,25], the animals
were sorted into four groups (6 mice/group; 2 grafts per kidney).
Treatment assignments were to sunitinib or inactive vehicle
(negative control). Sunitinib was administered as a 0.5%
carboxymethyl cellulose suspension using a dosage of 40 mg/kg
body weight (orally; once daily, for two weeks) found efficacious for
a variety of mouse xenograft models, as described elsewhere [26].
The mice were provided with food and water ad libitum and
monitored daily for changes in general health and signs of stress,
including body weight loss, diarrhea, changes in food/water
intake, appearance (hunched posture, sunken eye, labored
breathing) and behavior (lethargy). Effects on tumor growth were
assessed by measurement of tumor volume at necropsy using
calipers and the formula: volume (mm
3)=0.526length6width6
height (in mm), as previously described [25] and by histochemical
analysis of tumor tissue sections (see below).
Measurement of tyrosine phosphorylation of VEGFR2
and PDGFRb in xenografts via Western blotting
Within 2 h of the last administration of sunitinib in the above
efficacy studies, xenografts from treated and control mice were
snap frozen in liquid nitrogen and stored at 280 C for subsequent
use. Lysates were prepared by homogenization of tissues with cold
lysis buffer (50 mM HEPES pH 7.5, 150 mM NaCl, 1.5 nM
MgCl2, 10% v/v glycerol, 1% Triton X-100, 1% sodium
orthovanadate, 2 mM NaF, 2 mg/mL aprotinin, 2 mg/mL leu-
peptin, and 2 mg/mL pepstatin-A) as described elsewhere [26].
For immunoprecipitation, protein amounts were adjusted to
500 mg. Proteins were precleaned with protein A-Sepharose
(Cat. No. 16-125, Upstate Biotechnology Inc., Lake Placid, NY)
for 15 min at 4C. Supernatants (1 mL) were incubated with 4 mg
rabbit anti-VEGFR2 (Cat. No. 07-716) or anti-PDGFRb (Cat.
No. 05-825) antibodies (Upstate Biotechnology Inc.) for 90 min at
4C and, following addition of 25 mL 50% (v/v) Protein A-
Sepharose, further incubated for 60 min at 4C. Antigen-antibody-
bead complexes were washed at least three times with lysis buffer,
followed by addition of 25 mL loading buffer and boiling for 1 min
for protein elution. Proteins were separated by 5% SDS-PAGE gel
and then transferred onto PVDF membrane for detection of
phosphorylated tyrosine using a mouse monoclonal antibody to
phosphotyrosine (Cat. No. sc-7020, Santa Cruz Biotechnology
Inc.). Membranes were subsequently stripped and reprobed for
detection of total VEGFR2 and PDGFRb using the same antibody
preparations used for immunoprecipitation.
Apoptosis detection
Paraffin-embedded tissue sections (5 mm thick) were examined
by TUNEL assay (ApopTagH Apoptosis Detection Kit, Chemicon,
A Genomic Approach for Personalized Medicine
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incubated for 15 min with 20 mg/mL proteinase K at room
temperature and then thoroughly washed in distilled water. DNA
fragments produced by the apoptotic process were tagged with
digoxigenin nucleotides via a 60 min incubation at 37uC with
terminal deoxynucleotidyl transferase (TdT) in a humidity
chamber. The sections were then rinsed and incubated for
30 min at room temperature with anti-digoxigenin conjugated
with fluorescein. After counterstaining with 49-6-diamidino-2-
phenylindole (DAPI), the slides were examined for the percentage
of fluorescein-tagged cells using a Zeiss Axioplan-2 fluorescence
microscope.
Histology, immunohistochemistry, and microvessel
density estimation
Preparation of paraffin-embedded tissue sections, their staining
and immunohistochemical analyses were carried out as previously
described (23, 24). Anti-von Willebrand factor VIII antibody (Cat.
No. A0082, DAKO Diagnostics Canada Inc.; 1:200) was used for
identification of microvessels. All tissue sections were lightly
counterstained with 5% (w/v) Harris hematoxylin (H&E). Control
sections were processed in parallel with rabbit non-immune IgG
(Dako, Carpinteria, CA) used at the same concentrations as the
primary antibodies. Microvessel density, i.e., the number of blood
vessels per 6400 microscopic field, was determined via micro-
scopic analysis of von Willebrand factor VIII-stained tissue
sections.
Statistical analysis
Data are expressed as means 6 S.E.M. ANOVA was used to
compare multiple group mean values. Shaffer statistics and
Student’s t-test were used for analyzing any difference between
two groups. Comparison of the percentage of cells in different cell
cycle phases was performed with two-way ANOVA with use of
Figure 1. Whole genome expression profiling of clear cell ovarian tumors. (a) Graphic representation of whole genome expression profiling
of the Clear Cell Ovarian Cancer Specimen (CCOC) and Ovarian Surface Epithelium (OSE). (b) and (c) Comparison of qRT-PCR data and microarray data
of the six overexpressed and four underexpressed genes used for validation (d) Pathway analysis of differentially regulated genes identified in the
clear cell ovarian cancer microarray. Genes included in the analysis were required to have a fold change $1.5. Multiple probe sets were averaged for
each gene. Red, gene is up-regulated. Blue, gene is down-regulated.
doi:10.1371/journal.pone.0021121.g001
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statistically significant at P,0.05, except for the microarray
analysis, where significance was set at p,0.001.
Results
Whole genome expression profiles of microdissected
CCOC identifies differentially expressed genes
The gene expression patterns of RNA isolated from the epithelial
component of 10 clear cell ovarian cancer specimens isolated by
laser capture microdissection were compared to similarly isolated
RNA from 10 normal ovarian surface epithelium specimens using
Affymetrix U133 plus 2 arrays. After normalization and initial
analysis, 16,013 informative probesets passed filtering criteria.
Using a multivariate permutation test providing 95% confidence
that the number of false discoveries did not exceed 10%, 3,288
probesets for 2,559 genes were found to be differentially regulated,
defined by a 1.5-fold or greater difference in expression with a
statistical significance of p,0.001. Graphic representation of this
differentialgene expression canbeseeninFigure1a.Tovalidatethe
microarray data, 12 genes that were differentially expressed were
randomly selected for qRT-PCR analysis. Ten of the 12 genes were
differentially expressed on qRT-PCR, giving an overall microarray
validation rate of 83% (Figure 1b, c and Table S1).
Identification of activated pathways in CCOC
In order to identify activated pathways present within CCOC,
functional categories of differentially expressed genes were
identified using gene ontology (GO) analysis. Statistically signifi-
cant categories demonstrate a large number of genes involved in
carbohydrate metabolism, glucose metabolism, glycolysis, and
blood vessel development (Table 1). The 3,288 probesets and their
associated relative expression data when compared to OSE were
imported into PathwayStudio 6.0 software. Pathways involved in
angiogenesis, coagulation, glucose metabolism, cell proliferation,
and cell motility were evident (Figure 1d). For instance, HSPCA,
which has been shown to stabilize HIF1a (27), was found to be
over-expressed. Genes regulated by HIF1a involving glycolysis
(ENOl [27] and SLC2A1 [28]) and angiogenesis (PGF [29], VEGF
[30], and FLT1 [31]) were identified. Both PROS1 and F3 were
found to be dysregulated. F3 is up-regulated by FLT1 [32] and CP
[33]. NOTCH1, which was found to be over-expressed, has been
shown to up-regulate both VEGF [34] and SLC2A1 [35],
contributing to both the angiogenesis and glycolysis pathways.
Table 2 provides a more detailed description of these genes.
CCOC are resistant to hypoxia/glucose deprivation
induced necrotic death
The presence of a dominant activated pathway involving
angiogenesis and glycolysis in ovarian clear cell tumors suggested
that these cells have developed mechanisms to survive in low
oxygen and glucose conditions. This provides survival signals for
clear cell tumors under conditions where other tumors might die.
We tested the growth of ovarian cancer cell lines of papillary
serous and clear cell origin under the conditions of normoxia/
normal glucose (NN) compared with to hypoxia (1% O2) and
glucose deprivation (HG). Deprivation of oxygen and glucose had
a minimal effect on the growth of clear cell cell lines (ES2 and
TOV21G) when compared to serous cell lines (OVCAR 420 and
OVCAR429) which were essentially completely growth inhibited
(Figure 2a). Further we compared the doubling times of the cell
lines and the fold change in doubling time between the conditions
of NN and HG were calculated. The bar graph demonstrates a
statistically significant difference when the fold change in doubling
times is averaged by histotype, showing that the three clear cell
ovarian cancer cell lines were less affected by hypoxia/glucose
deprivation than the six serous cell lines (Figure 2b. p=0.0037).
These results highlight the importance of hypoxia-related and
glycolysis pathways in clear cell ovarian cancer.
A cell cycle analysis of serous cell lines after 48 hours in the
conditions of HG demonstrated a significant increase in the G1
phase as well as a decrease in S phase under the HG conditions.
However, only OVCA-420 demonstrated a more global effect of
HG with a significant increase in both G2/M phase (Figure S1). In
addition to cell cycle arrest, we observed a large portion of OVCA-
420 cells were detached after 48–72 hours of HG conditions, which
wasnot seeninES-2clearcellcell lines.Trypanblueexclusionassay
was performed on both cell lines which confirmed that 40% of cells
under HG were dead for OVCAR-420 and ES2 cell lines were
resistant to HG conditions (Figure 2c). To determine the
mechanism of cellular death, a proliferation assay was performed
under treatment with Z-VAD-FAK to see if cell death was
prevented. No decrease in cell death was noted suggesting that
apoptosis was not a major contributor to cellular death (Figure 2d).
This was supported by the lack of caspase activity after 24, 48, and
72 hours (Figure S2). A cellular necrosis assay was performed on
OVCA-420cellsgrowninhypoxia/glucose deprivationandshowed
a 100% increase in necrosis (Figure 2e).
siRNA targeting HIF1 a or ENO1 sensitizes CCOC cell lines
to HG conditions
The microarray results and the in vitro HG assays suggested
that clear cell cancers were protected from the growth inhibiting
effects of these stresses by the activation of specific pathways. To
validate this mechanistically we ‘‘knocked-down’’ key genes in
these pathways by using siRNA technology. Three clear cell
cancer lines (ES-2, TOV21G, and RMG1) were transfected with
siRNA targeting HIF1 a (hypoxia) and ENO1 (glycolysis).
Reduction of the expression of both genes at these cell lines
(Figure 3a) demonstrated significant growth inhibition to HG
conditions compared to control transfected cells. Both ES-2
and TOV21G cells demonstrated statistically significant growth
inhibition when transfected with siRNA targeting ENO1
Table 1. Gene Ontology categories found to have a
statistically significant higher number of genes than expected
by chance.
GO Category No. genes p value
Cytoskeleton 76 p,1e-07
Cell cycle 39 p,1e-07
DNA metabolism 37 p,1e-07
Carbohydrate metabolism 27 p,1e-07
Cell motility 17 p,1e-07
Blood coagulation 12 p,1e-07
Glucose metabolism 10 p,1e-07
Cell growth 10 p,1e-07
Glycolysis 8 p,1e-07
DNA repair 8 p,1e-07
Blood vessel development 5 p,1e-07
Microtubule cytoskeleton organization
and biogenesis
5p ,1e-07
doi:10.1371/journal.pone.0021121.t001
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correlated with the amount of growth inhibition; while RMG1
demonstrated growth inhibitionw i t hk n o c k d o w no fE N O 1 ,i t
was the least efficient of the three clear cell cell lines and this
amount of growth inhibition was not statistically significant
(p=0.12). Serous ovarian cancer cell lines OVCA420 and
OVCA429 were growth inhibited in hypoxia (1% O2) and
glucose deprivation (HG) conditions and the transfection with
siRNA targeting HIF1 a and ENO1 has limited effect on further
growth inhibition compared to the control transfected cells
(Figure 3c and d). Further the Knockdown of HIF1 a and
Enolase 1 was performed on clear cell cell lines ES-2 and
TOV21G using siRNA. Forty eight hours after transfection, the
proliferation assays were carried out for hypoxia/glucose
deprivation for another 24, 48, and 72 hour. This experiment
supports that HIF1 a and Enolase 1 expression are important
for the ability of clear cell ovarian cells to grow efficiently in
hypoxic/low glucose conditions (Figure 3e and f).
In vivo reduction at ENO1 or HIF1 a using siRNA-DOPC
with or without sunitinib inhibits CCOC tumor
progression in athymic nude mice
As our microarray pathway analysis revealed angiogenesis as a
critical pathway in clear cell ovarian cancer growth, we
Table 2. Pathway genes.
Entrez gene ID Gene Description Fold change Function
133 ADM Adrenomedullin 4.37 Angiogenesis, Cell proliferation and invasion.
966 CD59 CD59, Complement regulatory protein 22.47 Inhibitor of complement membrane attack
complex (MAC) action
1356 CP Ceruloplasmin 13.78 Copper homeostasis
1398 CRK v-crk sarcoma virus CT10 oncogene homolog (avian) 1.86 Cell proliferation, focal adhesion Cell motility
7852 CXCR4 Chemokine (C-X-C motif) receptor 4 4.42 Cell invasion and motility
2023 ENO1 Enolase 1 (alpha) 2.21 Glycolysis
2026 ENO2 Enolase 2(gamma, neuronal) 2.39 Glycolysis
2152 F3 Coagulation factor III (thromboplastin, tissue factor) 4.71 Thrombosis
2321 FLT1 fms-related tyrosine kinase 1 5.63 VEGF receptor, angiogenesis
3091 HIF1A Hypoxia-inducible factor 1, alpha subunit 2.64 Promoter for genes involved in angiogenesis
and glycolysis.
3098 HK1 Hexokinase 1 4.18 Glycolysis
3099 HK2 Hexokinase 2 5.85 Glycolysis
3320 HSPCA Heat shock protein 90kDa alpha, class A member 1 2.874 Protein binding
3624 INHBA Inhibin, beta A 4.16 Angiogenesis
182 JAG1 Jagged 1 (Alagille syndrome) 2.61 Notch ligand, cell proliferation
4193 MDM2 Mdm2, transformed 3T3 cell double minute 2 2.92 Oncogene
4851 NOTCH1 Notch homolog 1, translocation-associated (Drosphilia) 8.6 Cell fate decisions
5160 PDHA1 Pyruvate dehydrogenase (lipoamide) alpha 1 2.09 Glycolysis
5214 PFKP Phosphofructokinase, platelet 4.3 Glycolysis
5228 PGF Placental growth factor 3.35 Angiogenesis
5335 PLCG1 Phospholipase C, gamma 1 3.07 Cell motility
10544 PROCR Protein C receptor, endothelial (EPCR) 214.93 Binds activated protein C, inhibiting blood
coagulation
5627 PROS1 Protein S (alpha) 25.1 Prevents coagulation and stimulates
fibrinolysis
5728 PTEN Phosphatase and tensin homolog (mutated in multiple
advanced cancers 1)
22.43 Tumor suppressor
6392 SDHD Succinate dehydrogenase complex, subunit D, integral
membrane protein
21.82 HIF1a degradation
6513 SLC2A1 Solute carrier family 2 (facilitated glucose transporter),
member 1
3.76 Glucose transport
7980 TFPI2 Tissue factor pathway inhibitor 2 22.47 Inhibits tissue factor
7056 THBD Thrombomodulin 24.44 Activates protein C, inhibiting blood
coagulation
7078 TIMP3 TIMP metallopeptidase 3 (Sorsby fundus dystrophy,
pseudoinflammatory)
25.35 Inhibitor of matrix metalloproteinases
7422 VEGF Vascular endothelial growth factor 2.71 Angiogenesis
Differentially expressed genes identified in the clear cell microarray involved in coagulation, angiogenesis, cell proliferation, cell motility, and glucose metabolism
(average fold change $1.5; P,0.001).
doi:10.1371/journal.pone.0021121.t002
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effectsonclearcellovarian cancergrowth.Totestthis,weevaluated
the therapeutic potential of sunitinib in clear cell ovarian cancer.
Sunitinib is a small molecule inhibitor of receptor tyrosine kinases
(TKIs) such as VEGFR (vascular endothelial growth factor
receptor) and PDGFR (platelet-derived growth factor receptor)
tyrosine kinases. While we could have used other TKIs, sunitinib
waseasilyavailable and in preclinical studies. It was found to exhibit
robust antitumor and antiangiogenic activity in a variety of cancer
models. Inhibition by sunitinib of VEGF and PDGF signaling
pathways appears to be particularly critical for tumor-induced
angiogenesis. Recently, sunitinib has been approved by the FDA for
clinical therapy of renal clear cell carcinoma and gastro-intestinal
stromal tumors. To functionally validate the pathways in vivo,w e
applied siRNA technology along with antiangiogenic agents in
athymic nude mice orthotopic models. The ES2 cell line was used
since it reproducibly produced large tumors over a short period of
time. Tumor weight was found to be significantly reduced in ENO1
and HIF1a siRNA treated mice with respect to its control group
(Figure 4a). Likewise treatment of the mice with antiangiogenic
agent (sunitinib) produced large reduction in tumor weight.
Combination of siRNA and antiangiogenic agents produced
Figure 2. Clear cell ovarian cancer cell lines were more resistant to hypoxia/glucose deprivation than serous ovarian cancer cell
lines. (a) Cellular proliferation assays of ovarian cancer cell lines of clear cell and serous origin under different oxygen and glucose conditions. The
doubling times of the cell lines were compared, and the fold change in doubling time between the conditions of normal oxygen/normal glucose (NN)
and hypoxia/glucose deprivation (HG) were calculated. (b) The bar graph demonstrates a statistically significant difference when the fold change in
doubling times is averaged by histotype, showing that the three clear cell ovarian cancer cell lines were less affected by hypoxia/glucose deprivation
than the six serous cell lines (p=0.0037). (c)Trypan blue exclusion assay of OVCA-420 and ES2 cells grown in normal oxygen/normal glucose (NN) and
hypoxia/ glucose deprivation (HG) for 72 hours. (d) Proliferation assay of OVCA-420 cells incubated in NN, HG, and HG with Z-VAD-FAK. The addition
of Z-VAD-FAK did not alter the growth inhibition of HG. (e) Necrosis assay of OVCA-420 cells demonstrated a statistically significant increase in
necrosis when incubated in HG (p=0.003).
doi:10.1371/journal.pone.0021121.g002
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and tumor microvessel density estimations (Figure 4b,c).
Growth of patient-derived CCOC tissue xenografts
sensitive to sunitinib
As cancer models based on xenografts of cultured cancer cell
lines in general do not adequately represent the disease as it
present in humans, we used patient derived clear cell and serous
ovarian cancer tumors grafted under the renal capsule of NOD-
SCID mice to mimic the clinically relevant cancers. This
method allows high tissue perfusion and potentially rapid
development of graft microvasculature. More importantly, the
ovarian cancer tissues can be grown and serially transplanted
under renal capsules of NOD-SCID mice, with minimal
histological and genetic changes, and with retention of
sensitivity to cytotoxic chemotherapy. These patient-derived
cancer tissue lines are therefore very similar to the original
cancer specimens and, as such, their xenografts in NOD-SCID
mice provide ovarian cancer models that closely resemble the
patients’ malignancies. To further validate our findings we
tested patient tumor explants directly in NOD-SCID mice. As
shown in Figure 5a, treatment with sunitinib markedly inhibited
growth of the LTL175 clear cell cancer (P,0.01), whereas it
had essentially no effect on the growth of the serous carcinoma
lines LTL237, 247 and 259 (stable tumor size). To confirm that
the sunitinib had receptor tyrosine kinase inhibitory activity in
vivo, lysates of LTL247 and LTL175 xenografts were treated for
2 weeks with sunitinib or vehicle (control) and were examined
by western blotting for amounts of phosphorylated tyrosine
residues on VEGFR2 and PDGFRb proteins. As shown in
Figure 5b and 5c, there was active tyrosine phosphorylation of
both VEGFR2 and PDGFRb in the two tumors. The 2-week
treatment with sunitinib reduced tyrosine phosphorylation of
VEGFR2 and PDGFRb in both the serous carcinoma (LTL247)
and CCOC (LTL175) tissues to very low levels. Our genomic
data supports a model where clear cell cancers of the ovary have
activated pathways involving angiogenesis. We propose that this
explains, in part, their clinical aggressive behavior and rapid
tumor growth. As such, we hypothesize their growth would be
exquisitely sensitive to antiangiogenesis agents. Serous tumors
appear to have minimal activation of this pathway and as such
should be somewhat insensitive to these agents. The result of
Figure 3. Knockdown of HIF1a and ENO1 in three clear cell ovarian cancer cell lines. (a) Knockdown efficiency of siRNA molecules
targeting HIF1a and ENO1 in three clear cell ovarian cancer cell lines, assessed by quantitative real-time PCR. (b) The percent of growth inhibition
after transfection of siRNA molecules targeting HIF1a and ENO1. Growth was assessed after 24 hours of hypoxia/glucose deprivation *p=0.12,
**p,0.05,***p=,0.0001. (c, d) Knockdown efficiency of siRNA molecules targeting HIF1a and ENO1 in OVCA429 and OVCA420 and the percent of
growth inhibition after transfection of siRNA molecules targeting HIF1a and ENO1. (e, f) Effect of HIF1a and ENO1 knockdown on proliferation of ES-2
and TOV-21G clear cell cell lines (***p=,0.0001).
doi:10.1371/journal.pone.0021121.g003
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inhibit the target but the serous tumors are less dependent on
these pathways than clear cell tumors. This experiment confirms
t h i sb u ti ti sc r i t i c a lt oe n s u r et h i si sn o tt h er e s u l to fl a c ko fd r u g
effect on its target.
Differential effect of sunitinib treatment on tumor mass
and cell morphology/viability of CCOC xenografts
correlate with microvessel density
Subrenal capsule LTL175 xenografts treated for two weeks
with vehicle (controls) showed markedly enlarged tumor masses
(Figure 5a) which, as indicated by H&E staining of tissue
sections, consisted of viable cancer cells (Figure 5d.a). In
contrast, sunitinib-treated tumors showed much lower tumor
mass and lower cell numbers (Figure 5d.b) than controls. Since
sunitinib has anti-angiogenic activity [26], we investigated the
effect of the 2-week treatment with sunitinib on the microvessel
densities of LTL237, 247, 259 and 175 tumors by microscopic
analysis of von Willebrand factor VIII-stained tumor sections.
Whereas sunitinib had no significant effect on the microvessel
densities of the tumors of the three serous carcinoma tissue
lines, it led to markedly lower (,66%; P,0.01) microvessel
density of the LTL175 clear cell carcinoma tumors (Figure 5e).
Effect of sunitinib on apoptosis of LTL175 tumors
Immunohistochemical analysis of TUNEL-stained tissue sec-
tions showed that LTL175 ovarian clear cell carcinoma xeno-
grafts, treated for 2 weeks with sunitinib, had a substantially higher
number of apoptotic cells than control xenografts (Figure 5f). On
average, the number of apoptotic cells in a 4006microscopic field
was approximately 2-fold higher in the sunitinib-treated tumor
tissue (P,0.05) (Figure 5g).
Discussion
This is the first report of whole genome expression profiling of
microdissected CCOC specimens. We carried out a direct
comparison of our gene list with a publically available datasets
of clinical samples (GSE6008) [36]. GSE6008 contains expression
profiling for 8 clear cell carcinomas and 4 individual normal
ovary samples using Affymetrix HG_U133A array. Robust Mult-
chip Average (RMA) analysis identified 3365 genes using a two
sample T-test (p,0.001). Comparison of this gene list with our
CCOC gene list identified 731 common genes. Pearson’s Chi-
squared test with Yates’ continuity correction identified the
overlap between the two sets of genes (731 genes) is significant
and not due to chance (p-value,0.001). These 731 genes
correspond to 29% of our CCOC gene list. We were not
expecting a large overlap in these datasets because we generated
our CCOC gene list from the laser capture microdissected
epithelial component of clear cell ovarian cancers. These are pure
populations of epithelial cells without the contamination of
stromal components. In another sudy, Yamaguchi et al derived
an ovarian clear cell carcinoma gene signature using cell lines and
clinical samples expression analysis [37]. They have identified a
437 probe sets corresponding to 320 genes as the CCOC
signature. We have found 76 genes from this 320 genes overlap to
our gene signature and which was highly significant (p-
value,0.001). Of note, the CCOC signature reported by
Yamaguchi includes molecular networks of hypoxia-inducible
factor 1 (HIF1a) which is reported in our study.
Comparison of the CCOC microarray gene list with a similarly
generated gene list from microdissected serous ovarian tumors
[38], identified that 73% of genes in the list were unique to
CCOC. These unique genes likely explain the clinico-pathologic
properties of CCOC. For instance, a large number of genes
Figure 4. Effect of Enolase or HIF1 a siRNA-DOPC ± sunitinib on ovarian clear cell tumor progression in the female athymic nude
mouse model. (a) Tumor weight: ES2 cells (1610
6 cells/mouse) were injected intraperitoneal into mice. The mice were treated with control, Enolase
or HIF1 a siRNA-DOPC 6 sunitinib (n=10/group). Immunohistochemical staining for CD31 antigen was performed on frozen slides of tumor to
evaluate the number of tumor nodules (b) and tumor microvessel density (MVD) (c). (See Materials and Methods section for details).
doi:10.1371/journal.pone.0021121.g004
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may explain why patients with CCOC have been found to have a
higher incidence of thromboembolic events when compared to
patients with other epithelial ovarian cancers [10]. F3 is one such
gene [32], and is a major coagulation initiator. F3 is up-regulated
by both FLT1 and CP [32,33]. Furthermore, F3 is inhibited by
TFPI2 [39], which is down-regulated in our microarray. Other
down-regulated genes that are inhibitors of coagulation include
THBD, PROCR, CD59, and PROS1 [40,41].
More importantly, analysis of the CCOC data set revealed
major activated pathways involved in angiogenesis and gycolysis.
Both VEGF and its receptor, FLT1, were found to be up-
regulated, as well as INHBA. INHBA is a member of the
transforming growth factor-b superfamily that has been found to
be up-regulated by VEGF [42]. Furthermore, it has been found to
be an autocrine factor involved in tubulogenic morphogenesis by
up-regulating VEGF and FLT1 [42,43]. ADM is involved in
angiogenesis and is transcriptionally up-regulated by HIF1a [44].
Figure 5. Effect of sunitinib on the growth of patient-derived CCOC tissue xenografts. (a.) Effect of a two-week treatment with sunitinib
on growth of subrenal capsule xenografts in NOD-SCID mice (6 mice/group; 2 grafts per kidney) of transplantable serous (LTL237, 247 and 259) and
clear cell (LTL175) ovarian carcinoma tissue lines derived from patients’ cancers. Growth of the xenografts is expressed as % tumor volume
determined at necropsy by measurement with calipers. Data are presented as means 6 S.E.M. (b, c) Effect of sunitinib on VEGFR2 and PDGFRb
tyrosine phosphorylation as shown by Western blot analysis. Subrenal capsule xenografts of ovarian LTL247 serous carcinoma tissue and LTL175 clear
cell carcinoma tissue in mice, treated for 2 weeks with sunitinib or vehicle (control), were lysed and processed for Western blot analysis of VEGFR2 (b)
and PDGFRb (c) tyrosine residues. The results are representative of 3 experiments. (d) Representative H&E-stained tumor sections of control (d.a), and
sunitinib-treated (d.b) LTL175 tissue. (e) Effect of sunitinib on microvessel density of subrenal capsule xenografts in NOD-SCID mice of serous
(LTL237, 247, 259) and clear cell (LTL175) ovarian carcinoma tissue lines. Data are presented as the average number of blood vessels per 6400
microscopic field 6 S.E.M. (f) Effect of sunitinib on apoptosis in LTL175 xenografts in NOD-SCID mice treated with sunitinib for 2 weeks.
Representative tissue sections of control (f. a) and sunitinib-treated (f. c) TUNEL-stained tumor tissue and counterstained with DAPI (f. b, control; f.
d, sunitinib-treated); (g), percentage of apoptotic cells determined via microscopic analysis using a 4006microscopic field; data presented as means
6 S.E.M.
doi:10.1371/journal.pone.0021121.g005
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factorial, and our pathway analysis reveals cross-over with other
pathways. NOTCH1 has been shown to up-regulate VEGF and
SLC2A1 [34,35]. The VEGF receptor, FLT1, has been shown to
phosphorylate CRK and PLCG1, both of which are involved in
cell motility[45]. Our results suggest one important protein in this
pathway is HIF1a. The microarray suggests several mechanisms
for activation of the HIF1a pathway in CCOC. MDM2 was found
to be over-expressed, and it has been found to up-regulate HIF1a
expression [46]. HSPCA stabilizes HIF1a protein, avoiding
degradation via a VHL-independent pathway [47], and this gene
was found to be over-expressed as well. SDHD is involved in
HIF1a degradation [46], and was found to be under-expressed.
Multiple genes within glucose metabolism are up-regulated in
CCOC. SLC2A1 is involved in glucose transport, and HK1/HK2
and ENO1/ENO2 are involved in glycolysis. All are known to be
transcriptionally up-regulated by HIF1a [27,28,48]. HIF1a has
been found to help protect cells against apoptosis, and this effect is
mediated through the regulation of glucose transporters and
glycolysis enzymes [28]. In vivo studies evaluating the tumoricidal
effects of HIF1a disruption have demonstrated a greater
correlation with glucose metabolism disruption [49,50]. Over-
expression of ENO1 and HIF1a in CCOC also demonstrates a
clinical link to CCOC’s association with endometriosis. Up to 50%
of patients with endometriosis have been found to have
autoantibodies to enolase [51,52], possibly implying an immune
response to overproduction of enolase. We demonstrated over-
expression of ENO1 in both CCOC tumors and associated
endometriotic lesions (Figure S3). Furthermore, recent literature
has reported elevated HIF1a mRNA and protein levels in ectopic
endometrial implants [53].
The relevant importance of these activated pathways are
demonstrated in our in vitro and in vivo model systems. There is a
major phenotypic difference between clear cell and serous cell lines
in their rate of proliferation under in vitro conditions of HG.
Knockdown of genes in either pathway, sensitizes the clear cell
lines to HG conditions. This experiment suggests three major
points. First, this suggests that a mechanism for the poorer
prognosis for clear cell cancers when compared to the serous
histotype, may be the ability of the cells to survive in the
environment with limited oxygen and nutrients. Clear cell cancer
cells were less affected by these stressful conditions when compared
to serous cell lines. Second, disruption of the either angiogenesis or
gycolytic pathways sensitizes these cells to these conditions,
implying that they play a role in providing these cells with a
survival advantage. Third, these pathways may serve as therapeu-
tic targets.
The in vivo importance of the angiogenesis and glycolytic
pathway for tumor growth was seen by systemic usage of small
molecule inhibitors or small interfering RNA (siRNA) in nude
mice. Since the microarray revealed mechanisms for activation of
pathways of angiogenesis, we evaluated the antitumor activity of
sunitinib. Sunitinib (SU11248; sutent), an antiangiogenic drug,
was effective at inhibiting cellular proliferation and in combination
with HIF1 a and enolase siRNA’s indicated a synergistic
antitumor activity, with a reduction in tumor nodule and tumor
microvessel density.
To provide an additional level of validation, patient derived
clear cell and serous ovarian cancer tumors were grafted under the
renal capsule of NOD-SCID mice to mimic the clinically relevant
cancers. This method allows high tissue perfusion and potentially
rapid development of graft microvasculature. More importantly,
the ovarian cancer tissues can be grown and serially transplanted
under renal capsules of NOD-SCID mice, with minimal
histological and genetic changes, and with retention of sensitivity
to cytotoxic chemotherapy. These patient-derived cancer tissue
lines are therefore very similar to the original cancer specimens
and, as such, their xenografts in NOD-SCID mice provide ovarian
cancer models that closely resemble the patients’ malignancies
[24,25]. Sunitinib markedly reduced the growth and the
microvessel density of the clear cell carcinoma xenografts, it did
not significantly affect the tumor volume nor the microvessel
density of any of the three serous carcinomas.
Based on our microarray and results of knockdown and patient
derived tumor xenografts experiments, angiogenesis and glycolysis
pathways appear to be important in the survival and progression of
CCOC. The marked effect of sunitinib on the growth and viability
of the clear cell xenografts as distinct from the serous carcinoma
xenografts indicates that sunitinib is potentially useful for targeted
therapy of CCOC. Our studies with combination therapy of
sunitinib and RNAi demonstrate synergistic anti tumor activity in
CCOC and these results provide a rational basis for specific
therapy in these patients. Drugs targeting angiogenesis (antibodies
or TKIs) along with ones which inhibit tumor metabolism (mTor
inhibitors) would be one possible choice.
Supporting Information
Figure S1 Cell Cycling analysis of OVCA420 (serous)
and ES-2 (clear cell). After 48 hours of normal oxygen/normal
glucose (NN) and hypoxia/glucose deprivation (HG), a cell cycling
analysis was performed, demonstrating a significant increase in the
both G2/M phase in only the OVCA420 cell line.
(DOC)
Figure S2 Caspase assay for OVCA420. Caspase-3
activity was determined by relative fluorescence per mg
protein (see methods section for details).
(DOC)
Figure S3 Immunohistochemical staining for ENO1.
Both endometriotic lesions (left) and associated clear cell ovarian
tumors (right) strongly stain for enolase 1 (ENO1).
(DOC)
Table S1 qRT-PCR analysis of randomly selected 12
genes and corresponding primer sequences. * Student T-
test P-value.
(DOC)
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